Last reviewed · How we verify
NCT05086003
Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction
Phase 2 trial testing Combined kidney and bone marrow transplantation in Renal Transplantation in 20 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Rabin Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 19 January 2016 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Combined kidney and bone marrow transplantation
Conditions studied
- Renal Transplantation — all drugs for Renal Transplantation →
Sponsor
Rabin Medical Center
Who can join
Adults 18 to 65, any sex, with Renal Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Combined transplantation of kidney and bone marrow between HLA-matched sibling donor-recipient pairs to induce immune tolerance in order to enable complete discontinuation of immunosuppressive therapy without kidney rejection. Hematopoietic stem cells are collected from the donor 4 to 8 weeks before kidney transplantation, CD34 cells are enriched by positive selection and cryopreserved. The day after kidney transplantation the recipient starts conditioning therapy with thymoglobuline, total lymphoid irradiation, steroids, tacrolimus and mycophenolate mofetil. Eleven days after kidney transplantation the stem cell graft is thawed and infused to the recipient. If mixed donor chimerism is successfully maintained more than 6 months without rejection, then immunosuppression may be tapered off until complete discontinuation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cell therapies for immune-mediated disorders.
Wiewiórska-Krata N, Foroncewicz B, Mucha K, Zagożdżon R. · · 2025 · cited 3× · PMID 40206475 · DOI 10.3389/fmed.2025.1550527
Verify or expand the search:
- PubMed search for NCT05086003
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Transplantation
Currently open trials in the same condition.
- NCT07294183 — The Effect of Emotion-Focused Intervention on Emotion Regulation and Well-Being of Individuals With Transplantation · NA · recruiting
- NCT07045467 — Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study · Phase 1 · recruiting
- NCT06406179 — Evaluation of the Efficacy of Dd-cfDNA in Routine Patient Care in Kidney Transplant Recipients" · NA · recruiting
- NCT06026592 — Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients · recruiting
- NCT03266393 — Envarsus XR® in Adolescent Renal Transplant Recipients · Phase 4 · active not recruiting
Other Rabin Medical Center trials
Trials by the same sponsor.
- NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
- NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
- NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
- NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05086003 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
- Last refreshed: 28 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05086003.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing